Related references
Note: Only part of the references are listed.Multicentric evaluation of the new HemosIL Acustar(R) chemiluminescence ADAMTS13 activity assay
Cristina Pascual et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)
Real-world experience with caplacizumab in the management of acute TTP
Tina Dutt et al.
BLOOD (2021)
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study
Francesca Schieppati et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Linus A. Voelker et al.
BLOOD ADVANCES (2020)
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura
X. Long Zheng et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP
Paul Coppo et al.
BLOOD (2020)
Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry
Ilaria Mancini et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
Anand Padmanabhan et al.
JOURNAL OF CLINICAL APHERESIS (2019)
Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
Wolfgang Miesbach et al.
ORPHANET JOURNAL OF RARE DISEASES (2019)
Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity
Carla Valsecchi et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
M. Scully et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Treatment of acquired Thrombotic Thrombocytopenic Purpura in the US remains heterogeneous: Current and future points of clinical equipoise
Marshall A. Mazepa et al.
JOURNAL OF CLINICAL APHERESIS (2018)
How we treat thrombotic thrombocytopenic purpura: Results of a Canadian TTP practice survey
Christopher J. Patriquin et al.
JOURNAL OF CLINICAL APHERESIS (2017)
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies
M. Scully et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015
Evaren E. Page et al.
BLOOD ADVANCES (2017)
Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura
Evaren E. Page et al.
BLOOD (2016)
Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP/thrombotic microangiopathy registry
P. Blombery et al.
INTERNAL MEDICINE JOURNAL (2016)
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy
Eric Mariotte et al.
LANCET HAEMATOLOGY (2016)
Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features
Jessica A. Reese et al.
PEDIATRIC BLOOD & CANCER (2013)
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center
Antoine Froissart et al.
CRITICAL CARE MEDICINE (2012)
Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011
Sumit Som et al.
TRANSFUSION (2012)
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
Marie Scully et al.
BLOOD (2011)
Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features
Marie Scully et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry: The swiss connection
James N. George et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity
Silvia Ferrari et al.
BLOOD (2007)
Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias
SL Allford et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Share Paper
